NCT03501368View on ClinicalTrials.gov

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

October 28, 2022

Study Completion Date

January 31, 2026

Conditions
MelanomaUnresectable MelanomaAdvanced Melanoma
Interventions
DRUG

Ceritinib

Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)

DRUG

Trametinib

Participants will take trametinib by mouth at a dose of 2 mg daily

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER